Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
This article was originally published in The Gray Sheet
Executive Summary
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum
You may also be interested in...
Northstar Neuroscience Says It Has The Cash To Overcome EVEREST Setback
Northstar Neuroscience says it has enough cash reserves to continue developing its cortical stimulation technology for tinnitus and depression, despite the disappointing results of the first pivotal trial for a stroke indication
CMS denies coverage for VNS Therapy depression indication
Medicare agency issues national noncoverage determination for Cyberonics' VNS Therapy vagus nerve stimulation implant for treatment resistant depression (TRD) on May 4. The action follows a Feb. 5 noncoverage proposal (1"The Gray Sheet" Feb. 12, 2007, p. 10). The agency "has determined that there is sufficient evidence to conclude that vagus nerve stimulation is not reasonable and necessary for treatment resistant depression," CMS says. Last July, Cyberonics had requested coverage for TRD patients who either have been previously treated with or have refused treatment with electroconvulsive therapy, or have been previously hospitalized for depression. As a result of the depression reimbursement setback, Cyberonics has elected to refocus on its core business - which is centered on VNS Therapy's epilepsy indication...
Neuronetics Anti-Depression Device Not Equivalent To Shock Therapy – Panel
Neuronetics' NeuroStar transcranial magnetic stimulation system is not substantially equivalent to electroconvulsive "shock" therapy for treatment of major depressive disorder, FDA's Neurological Devices Panel concluded Jan. 26